Millions of Americans feel confused and frustrated in their search for quality healthcare coverage.
Between out-of-control costs, countless inefficiencies, a lack of affordable universal access, and little focus on wellness and prevention, the system is clearly in dire need of change.
Hosted by healthcare policy and technology expert Marc S. Ryan, the Healthcare Labyrinth Podcast offers accessible, incisive deep dives on the most pressing issues and events in American healthcare.
Marc seeks to help Americans become wiser consumers and navigate the healthcare maze with more confidence and certainty through the Healthcare Labyrinth website.
Marc is an unconventional Republican who believes that affordable universal access is a wise and prudent investment. He recommends common-sense solutions to reform American healthcare.
Tune in every week as Marc examines the latest developments in the space, offering analysis, insights, and predictions on the changing state of healthcare in America.
On this episode of the Healthcare Labyrinth Podcast, Marc reviews drug pricing in America relative to developed countries around the world.
Marc talks about America’s current standing with drug pricing, as well as a list of ten selected drugs that are in discussion for pricing negotiations within international markets overall.
Listen in to learn how countries across nations approach drug pricing and spending.
Retail drugs are approximately 10% of overall healthcare cost
Drug spending is primarily driven by brand drugs
America often spends more on healthcare than other developed countries
List Prices in America are three times higher than prices in other countries
America has an opaque drug supply channel
Countries across the world use reference pricing and international reference pricing
A number of drugs are excluded from pricing negotiations due to specific provisions
Net Prices in America are higher compared relative to most other developed countries
Economic and company trends impact aspects of the pricing ranges
Drug industry studies offer conflicting predictions on changes in drug maker revenue and innovation
Connect with Marc